FP7Индивидуална стипендия2014–2016

PLANTMEDs · Potential Antimalarial and Anticancer Lead Compound Discovery from Cameroonian Medicinal Plants

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2014-11-01 → 2016-10-31
Финансиране от ЕС
309 235 €
Участници
2
Схема
MC-IIF

Линиите свързват координатора с партньорите.

Накратко на български

Лечебни растения от дъждовните гори на Камерун, като видове от семейството на рутовите, се анализират за откриване на вещества с противоракови и антималарийни свойства. Това помага за създаването на препарати, с които местното население да се бори по-ефективно срещу тези заболявания.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Potential Antimalarial and Anticancer Lead Compound Discovery from Cameroonian Medicinal Plants

PEOPLE MARIE CURIE ACTIONS International Incoming Fellowships (IIF). Call: FP7-PEOPLE-2013-IIF. Project: PLANTMEDs N°629482 The objective of this project was to discovery potential anticancer and antimalarial lead compounds from Cameroonian rain forest plants and if possible to produce pre-processed fractions containing the active agents of medicinal plant extracts of Cameroon allowing the local populations to fight successfully against cancer and malaria. Thereby, selection of plants concentrated on species belonging to families with recorded effectivity in traditional Cameroonian medicinal use, based on the idea that these chemically and pharmacologically untapped members might hold the key to novel valuable leads for the pharmaceutical industry. I. Materials and Methods I.1. Plants Material The plants selected for the project, namely Fagara claessensii, Fagara poggei and Citrus reticulata from the family of Rutaceae - the latter added in the course of the project - as well as Hannoa ferruginea and Pierreodendron grandifolium from the family of Simaroubaceae were taxonomically identified in the Cameroonian rainforest together with a botanist, and vouchers were deposited at the Herbarium Yaoundé, Cameroon. In order to follow the rules set up by the Rio Convention on biological diversity, for each of the above species ten plants were located in the field. Small samples from each part of each tree (bark, roots, leaves, fruits/seeds) were collected to make a total of 5 kg for each part of each plant. I.2. Extraction and bioassay guided isolation Soxhlet extraction of the air dried and powdered each plant yielded - after evaporation under reduced pressure three fractions (n-hexane (Hex), dichloromethane (DCM) and methanol (MeOH)). These extracts were submitted to the 3-(4,5-dimethylthiazol-2-yl)-2,5-dphenyltetrazolium bromide (MTT) cytotoxicity/viability assay employing cancer cell lines A549, MCF7, PC3 and PNT2 and heam polymerisation. The most active extract against all three cancer cell lines and/or malaria assay were subjected to Vacuum Liquid Chromatography (VLC) on TLC grade silica gel as the stationary phase. Elution was performed with mixtures of n-hexane and ethyl acetate (EA), namely 20% of EA in Hex, 50% of EA in Hex and 70% of EA in Hex to give three fractions. The active fractions, which were then submitted to column chromatography over silica gel 60 using a gradient system of n-hexane, CH2Cl2, ethyl acetate and MeOH. Finally, some isolated compound were submitted to the MTT assay and heam polymersation to identify the active compound. II. Results and discussion II.1. Phytochemical investigation of Zanthoxylum claessensii (synonym Fagara claessensii) One new derivative of tirucallane together with twenty known compounds, were isolated from the hexane and dichloromethane (DCM) extracts of the bark and roots of Zanthoxylum claessensii (De Wild.) P. G. Waterman. The structures of all compounds were determined by comprehensive spectroscopic analyses (1D and 2D NMR and EI- and ESI–MS) as: citracridone II, citracridone III, citracridone I, 5-hydroxynoracronycine, 5-methoxynoracronycine, medicacridone, 5-methoxypsoralene, 5,8-dimethoxypsoralene, scopoletin, 7-methoxy-6-prenylcoumarine, marmesin, atalantoflavone, 2-methoxy-7,8-dehydroruteacarpine, 3,4-secotirucalla-4(28),7,24-triene-3,21-dioic acid, 1β-hydroxy-3,4-secotirucalla-4(28)-7,24-trièn-3,21-dioic acid, butilinic acid, lupeol, stigmasterol, β-sitosterol, β-sitosterol-3-O-β-D-glucopyranoside and stigmastérol-3-O-β-D-glucopyranoside. Some isolated compounds displayed a moderate level of cytotoxic activity against the human Caucasian prostate adenocarcinoma cell line PC-3, with IC50 values of 13.4 and 20.6 mM. II.2. Phytochemical investigation of Zanthoxylum poggei (synonym Fagara poggei) The stem bark of Zanthoxylum poggei (Engl.) P. G. Waterman, was extracted with CH2Cl2 and subjected to bioassay-guided fractionation based on its inhibitory activity against the oxidative burst of whole blood (90%). This extract was subjected to column chromatography (silica gel) and preparative TLC to afford two new and nine known compounds (Fig. 2). The structures of all compounds were determined by comprehensive spectroscopic analyses (1D and 2D NMR and EI- and ESI–MS) as poggeicridone, citracridone III, citracridone I, 5-hydroxynoracronycine, 2-methoxy-7,8- dehydroruteacarpine, 5-methoxynoracronycine, 2-hydroxyruteacarpine, 2-methoxyruteacarpine, 5,8,13,14-tetrahydro-2-methoxy-14-methyl-5-oxo-7H-indolo[20,30:3,4]pyrido[2,1-b]quinazolin-6-ium chloride, lupeol and β-sitosterol. All isolated compounds exhibited strong suppressive effects on the phagocytosis response upon activation with serum opsonized zymosan in the in vitro oxidative burst studies using whole blood. The IC50 values were in the range of 12.0-25.9 μM. These compounds displayed a moderate level of cytotoxic activity against the human Caucasian prostate adenocarcinoma cell line PC-3, with IC50 values of 15.8 and 22.1 μM (the IC50 value of the positive control standard doxorubicin was IC50 0.9 μM). II.3. Phytochemical investigation of Citrus reticulata Blanco 1.2 kg of bark material of Citrus reticulata Blanco was subjected to column chromatography (silica gel) and preparative TLC to afford seven known compounds identified as scoparone, xanthyletin, β-amyrin, lupeol, stigmasterol, β-sitosterol and palmitic acid. In vitro assays show that the stem bark of C. reticulata widely used in Cameroon against tumours is probably a good crude drug treatment against lung, breast and prostate cancer. 70% EA in Hex fraction of the stem bark of C. reticulata show good activity against lung, breast and prostate cancer and could be used for the development of new anticancer agents. Moreover, first assays display very low toxicity of a Hex extract fraction against a human normal prostate cell line. II.4. Phytochemical investigation of Hannoa ferruginea Soxhlet extraction of 3.2 kg of bark material of Hannoa ferruginea led - after evaporation under vacuum - to 24.5 g of Hex, 34.6 g of DCM and 345.2 g of MeOH extract. These extracts were tested against cancer cell lines A549, MCF7 and PC3 (in addition to the normal cell line PNT2) using the MTT assay. Etoposide was also used as the positive control. In the following, the 50% and 70% of EA in Hex fractions were subjected to column chromatography (silica gel) and preparative TLC to afford two new coumarinolignanes, two new canthin-6-one alkaloids, two new stiblenes and twelve known compounds, identified as ferrunolignane A and B , cleomiscosin A, furrunoide A and B, 1-methoxycanthin-6-one, 1-hydroxycanthin-6-one, 5-methylcanthin-6-one, canthin-6-one (39), 1-methoxycanthin-6-one-3-oxide, canthin-6-one-3-oxide, β-carboline-1-propionic acid, ferrunoside A and B. The structures of compounds were determined by comprehensive spectroscopic analyses (1D and 2D NMR and EI-MS) and by comparison with the reported data. Conclusion The results obtained during this project are interesting and confirm the use of these plants by the rural population for the treatment of parasitic diseases and tumors. The results of the antimalarial tests as well as the phytochemical and pharmacological studies of the other parts of Hannoa ferruginea are still in progress. The bark of Citrus reticulata widely used in Cameroon against tumors turns out to be probably a good crude drug treatment against lung, breast and prostate cancer when extracted with hexane or dichloromthane. First assays showed very low toxicity of a hexane extract fraction in vitro. However, further in vitro and in vivo tests will be necessary before any recommendation of this drug can be given. A positive outcome might initiate formulation studies for the development of a safer anticancer plant product from the bark of this plant, to be manufactured in developing countries. The various techniques acquired during his stay here, will be transfered to PhD and Master Students of the University of Douala. This will enable them to develop their potentials.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Cameroon enjoys a rich biota including a plethora of medicinal plants, which have traditionally been used for hundreds ofyears to treat various ailments, and form the basis of the country’s primary healthcare system. Medicinal plants of thegenera Fagara (F: Rutaceae), and Hannoa and Pierreodendron (F: Simaroubaceae) belong to the Cameroonian flora, andare used by the local people to treat malaria, cancer, rheumatism, bacterial infections, pain, inflammations, typhoid, skininfection and other serious disorders. Previous studies carried out on certain species of these genera afforded variousphytochemicals (quassinoids, furoquinoleine, acridones, cathinone alcaloids, triterpenoids and steroids) and revealedinteresting pharmacological properties (cytotoxicity, antiplasmadial activities). This project proposes to employ acombination of chemical fingerprinting-based dereplication, assay-guided fractionation and reversed-phase preparative highperformance chromatographic methods to identify potential anticancer and antimalarial lead compounds from plants of thegenera mentioned above, selected on the basis of ethnobotanical information as well as literature data. The structures ofthe isolated compounds will be elucidated by spectroscopic means (UV, IR, MS, NMR and X-ray). Structural modification toincrease activity of compounds will be carried out applying modern semisynthetic approaches in order to establish structureactivityrelationships. Total synthesis will also be carried out to increase to quantity of the lead compounds. Suitable in vitrobioassays, relevant to cytotoxicity, antimalarial and toxicity determination will be utilised to aid isolation processes as well asfor the determination of bioactive potencies of the isolated lead compounds. The main objective is to discover and developbioactive natural products and their analogues as clinical trial candidates.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз